Literature DB >> 19221292

Demyelinating events in early multiple sclerosis have inherent severity and recovery.

E M Mowry1, M Pesic, B Grimes, S Deen, P Bacchetti, E Waubant.   

Abstract

BACKGROUND: It is unclear whether the severity of and recovery from the initial demyelinating event (IDE) are recapitulated in subsequent multiple sclerosis (MS) relapses. We sought to identify the factors associated with relapse severity and recovery and to evaluate whether events have inherent severity or recovery.
METHODS: Patients seen at the UCSF MS Clinic within 1 year of disease onset were identified from a prospective database. Ordinal logistic regression was used to analyze predictors of three-level categorizations of event severity and recovery.
RESULTS: We identified 330 patients with MS or clinically isolated syndrome; 152 had a second event and 63 had a third event. Nonwhite and younger patients were at an increased risk of more severe demyelinating events. A severe prior event predicted a substantial increase in the odds of being above any given severity cutoff for a severe subsequent event (for second event severity, odds ratio [OR] = 5.62, 95% confidence interval [CI] [2.39, 13.26], p < 0.0001; for third event severity, OR = 6.74, 95% CI [1.67, 27.18], p = 0.007). Similarly, poor recovery of the IDE predicted poor second event recovery (OR = 5.28, 95% CI [1.95, 14.25], p = 0.001), while fair or poor second event recovery predicted about a 5- or 13-fold increase in the odds of poor third event recovery. A more severe event also predicted a substantial increase in the odds of poor recovery.
CONCLUSIONS: Patients with severe presentation and poor recovery at disease onset continue on a similar trajectory with subsequent demyelinating events. Whether genetic or other biologic factors are responsible for this pattern remains to be determined.

Entities:  

Mesh:

Year:  2009        PMID: 19221292      PMCID: PMC2677540          DOI: 10.1212/01.wnl.0000342458.39625.91

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.

Authors:  M P Amato; G Ponziani; M L Bartolozzi; G Siracusa
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

2.  A pilot study of MRI activity before and during interferon beta-1a therapy.

Authors:  E Waubant; D E Goodkin; R Sloan; P B Andersson
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

3.  Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

Authors:  J G Phadke
Journal:  Brain       Date:  1990-12       Impact factor: 13.501

4.  Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis.

Authors:  B A C Cree; O Khan; D Bourdette; D S Goodin; J A Cohen; R A Marrie; D Glidden; B Weinstock-Guttman; D Reich; N Patterson; J L Haines; M Pericak-Vance; C DeLoa; J R Oksenberg; S L Hauser
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

5.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

6.  Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness.

Authors:  J F Kurtzke; G W Beebe; B Nagler; L T Kurland; T L Auth
Journal:  J Chronic Dis       Date:  1977-12

7.  Axonal transection in the lesions of multiple sclerosis.

Authors:  B D Trapp; J Peterson; R M Ransohoff; R Rudick; S Mörk; L Bö
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

8.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

Review 10.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

View more
  21 in total

Review 1.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

Review 2.  Menopause in multiple sclerosis: therapeutic considerations.

Authors:  Riley Bove; Tanuja Chitnis; Maria Houtchens
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

3.  Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.

Authors:  Muhammad Taimur Malik; Brian C Healy; Leslie A Benson; Pia Kivisakk; Alexander Musallam; Howard L Weiner; Tanuja Chitnis
Journal:  Neurology       Date:  2014-05-21       Impact factor: 9.910

4.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

Review 5.  Neuroprotection in multiple sclerosis: a therapeutic approach.

Authors:  Amir-Hadi Maghzi; Alireza Minagar; Emmanuelle Waubant
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

6.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Authors:  Martina Novotna; M Mateo Paz Soldán; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; John H Noseworthy; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

Review 7.  Autoimmune diseases and reproductive aging.

Authors:  Riley Bove
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

Review 8.  Early Aggressive Treatment Approaches for Multiple Sclerosis.

Authors:  Alexandra Simpson; Ellen M Mowry; Scott D Newsome
Journal:  Curr Treat Options Neurol       Date:  2021-05-15       Impact factor: 3.598

9.  Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability.

Authors:  Marinos G Sotiropoulos; Hrishikesh Lokhande; Brian C Healy; Mariann Polgar-Turcsanyi; Bonnie I Glanz; Rohit Bakshi; Howard L Weiner; Tanuja Chitnis
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-05-28

10.  Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.

Authors:  Amy Perrin Ross; Alona Williamson; Jennifer Smrtka; Tracy Flemming Tracy; Carol Saunders; Constance Easterling; John Niewoehner; Nicole Mutschler
Journal:  Mult Scler Int       Date:  2013-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.